Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 95(3): e2478, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26817881

RESUMO

Hepatocellular carcinoma (HCC) is one of the leading causes of liver transplantation. In an attempt to predict their recurrence after liver transplantation, evaluation of tumor number and size, degree of histologic differentiation, and the presence of vascular invasion already have their importance established. In this context, the role of biologic markers such as alpha-fetoprotein (AFP) is still not clear. This retrospective cross-sectional study analyzed the AFP relationship with recurrence of HCC after orthotopic liver transplantation.The current study retrospectively analyzed data from 206 patients with a histopathologic confirmed HCC between 1997 and 2010.The overall survival rates at 1, 3, 5, and 14 years were 78.6%, 65.4%, 60.5%, and 38.7%, respectively. The frequency of recurrence was 15.5%, and recurrence was significantly associated with a lower survival rate (P < 0.001). No association was observed between survival and AFP level (P = 0.153). A correlation, however, was found between tumor recurrence and AFP level (P = 0.002). Univariate analysis of risk factors for recurrence revealed that an AFP level greater than 200 ng/mL, the number of tumors, the degree of cellular differentiation, and the presence of vascular invasion or satellite nodules were associated with relapse. By multivariate analysis, only an AFP level greater than 200 ng/mL remained as a risk factor.Although an elevated AFP level did not correlate with survival in HCC patients undergoing orthotopic liver transplantation, a high AFP level was associated with a 3.32-folds increase in the probability of HCC recurrence.


Assuntos
Biomarcadores/sangue , Carcinoma Hepatocelular/cirurgia , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Recidiva Local de Neoplasia/diagnóstico , alfa-Fetoproteínas/metabolismo , Adulto , Idoso , Brasil , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidade , Estudos Transversais , Feminino , Humanos , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida
2.
Rev. AMRIGS ; 55(3): 250-254, jul.-set. 2011. tab
Artigo em Português | LILACS | ID: biblio-835364

RESUMO

O carcinoma hepatocelular (CHC) é a principal causa de morte nos pacientes com cirrose. Corresponde à quinta neoplasia mais comum e terceira causa de morte por câncer no mundo. O objetivo do estudo é analisar a casuística da população com neoplasia de fígado atendida no Ambulatório de Nódulos Hepáticos de um centro terciário. Métodos: Estudo descritivo analítico transversal de uma população de 109 pacientes com diagnóstico de CHC entre março de 2005 e abril de 2010. Resultados: A média de idade dos doentes foi 58,31 anos e 73,4% eram do gênero masculino. Quanto à etiologia da cirrose, as principais causas foram infecção pelo vírus C (51,4%), associação vírus C e álcool (23,9%) e uso isolado de álcool (10,1%). De acordo com o escore Child-Pugh, 47,7% dos pacientes eram A, 37,6% eram B e 13,8% eram C. Em 77,1% somente um exame de imagem foi necessário para estabelecer o diagnóstico de CHC. Em 64,2% o diâmetro do maior nódulo excedia 3 cm. Em 17,4% foram detectados 4 nódulos ou mais e 17,4% possuíam invasão macrovascular ao diagnóstico. Tratamento curativo pôde ser oferecido a apenas 21% dos casos: 13,7% transplante hepático e 7,3% hepatectomia. O tempo médio de espera em lista de transplante foi 5,8 meses. Conclusões: A maioria dos pacientes com diagnóstico de CHC apresenta tumores em estágio intermediário ou avançado. Dessa forma, é imprescindível que se faça o diagnóstico da neoplasia em fase precoce, através do rastreamento periódico dos indivíduos em risco, aumentando assim a sobrevida desses pacientes.


Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. It is the fifth most common cancer and the third leading cause of cancer death worldwide. The aim of the study is to analyze a sample of the population with liver cancer treated at the Clinic of Liver Nodules in a tertiary center. Methods: A cross-sectional descriptive study of a population of 109 patients diagnosed with HCC between Mar 2005 and Apr 2010. Results: The mean age of patients was 58.31 years and 73.4% were males. Regarding the etiology of cirrhosis, the main causes were infection by hepatitis C virus (51.4%), an association of C virus and alcohol (23.9%), and use of alcohol in isolation (10.1%). According to Child-Pugh score, 47.7% were A, 37.6% were B and 13.8% were C. In 77.1% of patients only one imaging test was needed to establish the diagnosis of HCC. In 64.2% the diameter of the largest nodule exceeded 3 cm. In 17.4% of cases 4 or more nodes were detected and 17.4% had macrovascular invasion at diagnosis. Medical treatment could be provided to only 21% of cases: 13.7% liver transplantation and 7.3% hepatectomy. Mean time on waiting list was 5.8 months. Conclusions: Most patients diagnosed with HCC have tumors in intermediate or advanced stage. Therefore, it is essential to diagnose cancer at an early stage through regular screening of individuals at risk, thus increasing patient survival.


Assuntos
Humanos , Carcinoma Hepatocelular , Cirrose Hepática , Transplante de Fígado
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA